Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern

Abstract

Androgenetic alopecia (AGA), also referred to as male pattern baldness, is the most common cause of hair loss in both sexes in adulthood. An option for topical treatment that selectively tar− gets the metabolic pathways involved in the balding process is alfatradiol, an estrasterid without hormonal activity. In a drug monitoring study, efficacy and safety of alfatradiol (0.025 %) was assessed in 233 patients with AGA (192 women, aged 14 ± 76 years, and 41 men, aged 17 ± 56 years). After 7.5 months of treat− ment, trichograms of 112 patients (92 women, 20 men) were evaluated. Under treatment with alfatradiol the proportion of frontal anagen hair increased statistically significantly, in wom− en from 69 % to 77 % (means) and in men from 56 % to 65 %. The proportion of telogen hair decreased accordingly. In 12 % of wom− en and 21 % of men a further decline in the number of anagen hair was observed. Merely three patients (1,3 %) reported mild local adverse reactions. In conclusion, Alfatradiol appears to be ef− fective and safe in the topical treatment of AGA in both men and women.

Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation

“…Due to study by Wozel et al 23 , alfa-tradiol is involved more in stabilization or deceleration of hair loss, which is consistent with the results found in the previous placebo-controlled study of 51 patients (9 women) over 6 months by Van Neste and Rushton 24 .…”

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

“…Various experiments have shown that, in comparison with 17β-estradiol, 17α-estradiol did not exhibit estrogen activity or exhibited only very weak activity. In the treatment of androgenetic alopecia, the action mechanism of 17α-estradiol is to suppress 5α-reductase activity, which impedes the conversion of testosterone to the more potent metabolite DHT 5 , 22 , 23 . In addition, it inhibits 17β-dehydrogenase activity, resulting in a slowing of the conversion process of androstenedione to testosterone.…”

“…In a controlled, randomized double-blind study, 63% of the treated patients with 17α-estradiol showed a reduction of the amount of telogen hairs, whereas in the control group the same reduction was found in only 37% of the cases 23 . Wozel et al 22 reported that 17α-estradiol increases and maintains the rate of anagen hair in 88% of the treated patients. When compared with minoxidil 17α-estradiol showed relatively lower efficacy compared to minoxidil in hair density and thickness 5 .…”

Wenn die Haare fehlen – Haarausfall in der Gynäkologischen Praxis

“…Neben Minoxidil wird auch 17α-Estradiol (Alfatradiol) lokal eingesetzt, allerdings gibt es zu dieser Substanz nicht genug wissenschaftliche Studien [7,8].…”